EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets
The CHMP is holding an extraordinary meeting to discuss the emerging data for the sickle cell disease drug
Oxbryta was the first medicine approved that directly inhibits sickle hemoglobin polymerization, the root cause of SCD • Source: Shutterstock 
